Evidence Connections

Follow the evidence beyond the paper.

Follow source-linked research projects, organizations, FDA application actions, compound targets and genetic studies.

Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.

FDA application actionOctober 14, 2020

Pembrolizumab

Approved submission · SUPPL 85

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 14, 2020

Pembrolizumab

Approved submission · SUPPL 85

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 13, 2020

Cytarabine

Approved submission · SUPPL 8

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 13, 2020

Cytarabine

Approved submission · SUPPL 5

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 13, 2020

Glimepiride

Approved submission · SUPPL 7

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 9, 2020

bevacizumab

Approved submission · SUPPL 336

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 9, 2020

Bevacizumab

Approved submission · SUPPL 336

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 5, 2020

Doxycycline Hyclate

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 2, 2020

Ipilimumab

Approved submission · SUPPL 115

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 2, 2020

Pembrolizumab

Approved submission · SUPPL 70

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 2, 2020

Pembrolizumab

Approved submission · SUPPL 70

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 2, 2020

Nivolumab

Approved submission · SUPPL 89

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 2, 2020

hydrochlorothiazide

Approved submission · SUPPL 33

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 30, 2020

bevacizumab

Approved submission · SUPPL 334

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 30, 2020

Bevacizumab

Approved submission · SUPPL 334

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 28, 2020

hydrochlorothiazide

Approved submission · SUPPL 34

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 25, 2020

Nivolumab

Approved submission · SUPPL 86

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 18, 2020

Ipilimumab

Approved submission · SUPPL 112

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 18, 2020

Nivolumab

Approved submission · SUPPL 84

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 18, 2020

Nivolumab

Approved submission · SUPPL 85

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 16, 2020

propofol

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 16, 2020

Decitabine

Approved submission · SUPPL 15

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 16, 2020

tacrolimus

Approved submission · SUPPL 8

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 15, 2020

Glimepiride

Approved submission · SUPPL 15

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →